Pharmaceutical Strategy for Europe
In June 2020, the European Commission released a Roadmap and then launched an online public consultation on the Pharmaceutical Strategy for Europe. The Strategy aims to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. It will address:
- the life cycle of medicines from R&D to authorisation and patient access
- how to put scientific and technological advances into practice
- how to fill market gaps (e.g. new antimicrobials)
- lessons learnt from COVID-19 on how to better prepare for future pandemics.
HOPE answered the consultation, focusing on the need for a better affordability and availability of medicines, the necessity to tackle antimicrobial resistance and the need for better support for medical research at EU level.
Pharmaceutical in the Environment
From 22 November 2017 to 21 February 2018, the European Commission launched a consultation on pharmaceuticals in the environment. This consultation was part of a study gathering views on possible actions to address the risks from pharmaceuticals in the environment to support the development of a European Union (EU) strategic approach in this area.
HOPE answered the consultation in February 2018.
In relation with pharmaceuticals, HOPE also works on the following issues:
Pharmaceutical Health Information System